WO2000066106A3 - Use of benzodiazepines for treating autoimmune diseases induced by apoptosis - Google Patents
Use of benzodiazepines for treating autoimmune diseases induced by apoptosis Download PDFInfo
- Publication number
- WO2000066106A3 WO2000066106A3 PCT/US2000/011599 US0011599W WO0066106A3 WO 2000066106 A3 WO2000066106 A3 WO 2000066106A3 US 0011599 W US0011599 W US 0011599W WO 0066106 A3 WO0066106 A3 WO 0066106A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- benzodiazepine
- benzodiazepines
- disorders
- apoptosis
- Prior art date
Links
- 0 *N(c(cccc1)c1C(c1ccccc1)=NC1)C1=O Chemical compound *N(c(cccc1)c1C(c1ccccc1)=NC1)C1=O 0.000 description 2
- POLRJXLHUQNWKR-UHFFFAOYSA-N Cc1c(C(NC2N=C(c(cc3)ccc3O)c(cc(cc3)Cl)c3N(C)C2=O)=O)c(-c2ccccc2)n[o]1 Chemical compound Cc1c(C(NC2N=C(c(cc3)ccc3O)c(cc(cc3)Cl)c3N(C)C2=O)=O)c(-c2ccccc2)n[o]1 POLRJXLHUQNWKR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000614991A JP5127096B2 (en) | 1999-04-30 | 2000-04-27 | Use of benzodiazepines to treat autoimmune diseases induced by apoptosis |
IL14622200A IL146222A0 (en) | 1999-04-30 | 2000-04-27 | Therapeutic applications of pro-apoptotic benzodiazepines |
AU46802/00A AU782447C (en) | 1999-04-30 | 2000-04-27 | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
MXPA01011052A MXPA01011052A (en) | 1999-04-30 | 2000-04-27 | Therapeutic applications of pro-apoptotic benzodiazepines. |
AT00928586T ATE258439T1 (en) | 1999-04-30 | 2000-04-27 | USE OF BENZODIAZEPINES TO TREAT APOPTOSIS-INDUCED AUTOIMMUNE DISEASES |
CA2372150A CA2372150C (en) | 1999-04-30 | 2000-04-27 | Therapeutic applications of pro-apoptotic benzodiazepines |
US09/700,101 US7125866B1 (en) | 1999-04-30 | 2000-04-27 | Therapeutic applications of pro-apoptotic benzodiazepines |
DE60007960T DE60007960T2 (en) | 1999-04-30 | 2000-04-27 | Therapeutic applications of pro-apoptotic benzodiazepines |
EP00928586A EP1143946B1 (en) | 1999-04-30 | 2000-04-27 | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
US09/767,283 US7220739B2 (en) | 1995-05-18 | 2001-01-22 | Therapeutic application of pro-apoptotic benzodiazepines |
IL146222A IL146222A (en) | 1999-04-30 | 2001-10-29 | Use of compositions comprising benzodiazepines for the manufacture of medicaments for the treatment of conditions associated with dysregulation of cell death and pharmaceutical compositions thereof |
US10/427,211 US7572788B2 (en) | 1999-04-30 | 2003-05-01 | Compositions and methods relating to novel compounds and targets thereof |
US10/795,535 US7276348B2 (en) | 1999-04-30 | 2004-03-08 | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US10/886,450 US20060025388A1 (en) | 1999-04-30 | 2004-07-07 | Compositions and methods relating to novel compounds and targets thereof |
US10/935,333 US20050113460A1 (en) | 1999-04-30 | 2004-09-07 | Compositions and methods relating to novel compounds and targets thereof |
AU2005227385A AU2005227385C1 (en) | 1999-04-30 | 2005-10-27 | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
US11/585,492 US20070036854A1 (en) | 1999-04-30 | 2006-10-23 | Therapeutic applications of pro-apoptotic benzodiazepines |
US11/643,614 US8415343B2 (en) | 1999-04-30 | 2006-12-21 | Compositions and methods for inhibiting the proliferation of cells |
US11/807,046 US20090012065A1 (en) | 1999-04-30 | 2007-05-25 | Therapeutic applications of pro-apoptotic benzodiazepines |
US11/807,291 US20070299059A1 (en) | 1999-04-30 | 2007-05-25 | Compostions and methods relating to novel compounds and targets thereof |
US12/111,068 US7683046B2 (en) | 1999-04-30 | 2008-04-28 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
US12/728,716 US8168626B2 (en) | 1999-04-30 | 2010-03-22 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
US13/372,124 US20120165301A1 (en) | 1999-04-30 | 2012-02-13 | Benzodiazepine compositions for treating epidermal hyperplasia and related disorders |
US13/717,096 US8722667B2 (en) | 1999-04-30 | 2012-12-17 | Compositions and methods for inhibiting the proliferation of cells |
US13/896,876 US8809323B2 (en) | 1999-04-30 | 2013-05-17 | Therapeutic applications of pro-apoptotic benzodiazepines |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13176199P | 1999-04-30 | 1999-04-30 | |
US16551199P | 1999-11-15 | 1999-11-15 | |
US19185500P | 2000-03-24 | 2000-03-24 | |
US60/165,511 | 2000-03-24 | ||
US60/191,855 | 2000-03-24 | ||
US60/131,761 | 2000-03-24 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/881,037 Continuation-In-Part US6080588A (en) | 1995-05-18 | 1997-06-23 | Therapeutic methods for benzodiazepine derivatives |
US1802698A Continuation-In-Part | 1995-05-18 | 1998-02-02 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/700,101 A-371-Of-International US7125866B1 (en) | 1995-05-18 | 2000-04-27 | Therapeutic applications of pro-apoptotic benzodiazepines |
US09/767,283 Continuation US7220739B2 (en) | 1995-05-18 | 2001-01-22 | Therapeutic application of pro-apoptotic benzodiazepines |
US11/585,492 Continuation US20070036854A1 (en) | 1999-04-30 | 2006-10-23 | Therapeutic applications of pro-apoptotic benzodiazepines |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000066106A2 WO2000066106A2 (en) | 2000-11-09 |
WO2000066106A3 true WO2000066106A3 (en) | 2001-08-16 |
WO2000066106A9 WO2000066106A9 (en) | 2002-04-18 |
Family
ID=27384197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/011599 WO2000066106A2 (en) | 1995-05-18 | 2000-04-27 | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis |
Country Status (13)
Country | Link |
---|---|
US (5) | US7125866B1 (en) |
EP (4) | EP1398033B1 (en) |
JP (1) | JP5127096B2 (en) |
AT (2) | ATE433752T1 (en) |
AU (2) | AU782447C (en) |
CA (1) | CA2372150C (en) |
DE (2) | DE60007960T2 (en) |
DK (1) | DK1143946T3 (en) |
ES (1) | ES2214273T3 (en) |
IL (2) | IL146222A0 (en) |
MX (1) | MXPA01011052A (en) |
PT (1) | PT1143946E (en) |
WO (1) | WO2000066106A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994313B2 (en) | 2005-06-01 | 2011-08-09 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
Families Citing this family (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2785803B1 (en) * | 1998-11-17 | 2005-03-25 | Sanofi Sa | USE OF A SUBSTANCE BINDING TO THE PERIPHERAL RECEPTOR OF BENZODIAZEPINES IN THE TREATMENT OF SKIN STRESS |
US7572788B2 (en) | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US7276348B2 (en) | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
DK1143946T3 (en) | 1999-04-30 | 2004-06-07 | Univ Michigan | Use of benzodiazepines for the treatment of autoimmune diseases induced by apoptosis |
US20040176358A1 (en) * | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
NZ531117A (en) * | 2001-08-15 | 2006-03-31 | Univ Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
ATE398453T1 (en) | 2001-11-13 | 2008-07-15 | Ortho Mcneil Pharm Inc | SUBSTITUTED 1,4-BENZODIAZEPINES AND THEIR USE IN CANCER TREATMENT |
GB0221923D0 (en) * | 2002-09-20 | 2002-10-30 | Arrow Therapeutics Ltd | Chemical compounds |
KR101125899B1 (en) | 2002-09-20 | 2012-04-12 | 애로우 쎄라퓨틱스 리미티드 | Benzodiazepine derivatives and pharmaceutical compositions containing them |
WO2005004988A2 (en) * | 2003-05-01 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
EP1626711A4 (en) * | 2003-05-09 | 2010-10-06 | Univ Pennsylvania | Compositions and methods for treating cancer |
WO2004104491A2 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Percussively ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
US20050120397A1 (en) * | 2003-11-24 | 2005-06-02 | Hermann Steller | Compounds and methods for regulation of spermatid differentiation |
US20070293482A1 (en) * | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU2006203946B2 (en) | 2005-01-03 | 2009-07-23 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20090221559A1 (en) * | 2005-09-02 | 2009-09-03 | Jean-Francois Bonfanti | Benzodiazepines as hcv inhibitors |
BRPI0520554A2 (en) * | 2005-09-19 | 2009-06-13 | Arrow Therapeutics Ltd | use of a benzodiazepine or a pharmaceutically acceptable salt thereof, method for treating or preventing an hcv infection in a patient, benzodiazepine derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition |
US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
CA2628193C (en) * | 2005-11-01 | 2012-08-14 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
WO2007110337A1 (en) | 2006-03-29 | 2007-10-04 | F. Hoffmann-La Roche Ag | Pyridine and pyrimidine derivatives as mglur2 antagonists |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
WO2007146167A1 (en) * | 2006-06-09 | 2007-12-21 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
WO2008001357A2 (en) * | 2006-06-26 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Methods and kits for diagnosing cancer |
CL2008000491A1 (en) * | 2007-02-16 | 2008-08-22 | Tibotec Pharm Ltd | COMPOUNDS DERIVED FROM 1,1-DIOXO-1-TIA-DIAZA-DIBENZO CICLOHEPTENO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS; AND ITS USE TO TREAT HEPATITIS C. |
AU2008226532B2 (en) * | 2007-03-09 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
CA2685860A1 (en) * | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US8324258B2 (en) | 2007-09-14 | 2012-12-04 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
BRPI0820477A2 (en) | 2007-11-06 | 2015-06-16 | Univ Michigan | Benzodiazepinone compounds useful in the treatment of skin disorders |
GB2456562A (en) * | 2008-01-18 | 2009-07-22 | Petra Technology Ltd | Treatment of HIV/AIDS |
EP2145873A1 (en) * | 2008-06-17 | 2010-01-20 | Commissariat A L'energie Atomique | New compounds with activity that protects against the action of toxins and viruses in intracellular action mode |
EP2352724B1 (en) | 2008-09-11 | 2015-04-22 | The Regents of the University of Michigan | Aryl guanidine f1f0-atpase inhibitors and their medical use |
US8604023B2 (en) | 2009-04-17 | 2013-12-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
US9075060B2 (en) | 2009-06-16 | 2015-07-07 | Technion Research & Development Foundation Limited | Methods for diagnosing oral or oral-pharyngeal cancer |
US8673897B2 (en) | 2009-09-18 | 2014-03-18 | The Regents Of The University Of Michigan | Benzodiazepinone compounds and methods of treatment using same |
CN102753544A (en) | 2009-11-17 | 2012-10-24 | 密执安大学评议会 | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
WO2011062765A2 (en) | 2009-11-17 | 2011-05-26 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
CN102190631B (en) * | 2010-03-10 | 2014-10-29 | 中国人民解放军63975部队 | Preparation method of benzodiazepine compound |
TWI530489B (en) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds |
WO2014047390A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds as notch inhibitors |
CN105308030A (en) | 2012-09-21 | 2016-02-03 | 百时美施贵宝公司 | Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds |
US9273075B2 (en) | 2012-09-21 | 2016-03-01 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
WO2014047369A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinone compounds |
EP2897946B1 (en) | 2012-09-21 | 2016-11-16 | Bristol-Myers Squibb Company | N-substituted bis(fluoroalkkyl)-1,4-benzodiazepinone compounds as notch inhibitors |
WO2014047397A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors |
CN104822677A (en) | 2012-09-21 | 2015-08-05 | 百时美施贵宝公司 | Fluoroalkyl-1,4-benzodiazepinone compounds |
TWI614238B (en) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof |
CN104854094A (en) | 2012-09-21 | 2015-08-19 | 百时美施贵宝公司 | Fluoroalkyl dibenzodiazepinone compounds |
US9492469B2 (en) | 2013-04-04 | 2016-11-15 | Bristol-Myers Squibb Company | Combination therapy for the treatment of proliferative diseases |
SG10201910670RA (en) | 2015-03-31 | 2020-01-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
CA2992839A1 (en) | 2015-07-22 | 2017-01-26 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
US20170226129A1 (en) | 2016-01-15 | 2017-08-10 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
CN105693634B (en) * | 2016-03-17 | 2018-12-11 | 清华大学 | Compound and application thereof |
WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
CA3039124A1 (en) | 2016-10-04 | 2018-04-12 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
WO2018129287A1 (en) * | 2017-01-06 | 2018-07-12 | Enanta Pharmaceuticals, Inc. | Heteroaryldiazepine derivatives as rsv inhibitors |
AU2018221820B2 (en) | 2017-02-16 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of benzodiazepine derivatives |
WO2018226801A1 (en) | 2017-06-07 | 2018-12-13 | Enanta Pharmaceuticals, Inc. | Aryldiazepine derivatives as rsv inhibitors |
WO2019006291A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
US11091501B2 (en) | 2017-06-30 | 2021-08-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as RSV inhibitors |
EP3687543B1 (en) | 2017-09-29 | 2024-03-20 | Enanta Pharmaceuticals, Inc. | Combinations of pharmaceutical agents as rsv inhibitors |
US10501422B2 (en) | 2017-11-13 | 2019-12-10 | Enanta Pharmaceuticals, Inc. | Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives |
WO2019094920A1 (en) | 2017-11-13 | 2019-05-16 | Enanta Pharmaceuticals, Inc. | Azepin-2-one derivatives as rsv inhibitors |
WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
WO2019199908A1 (en) | 2018-04-11 | 2019-10-17 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as rsv inhibitors |
KR20210138684A (en) | 2019-03-18 | 2021-11-19 | 이난타 파마슈티칼스, 인코포레이티드 | Benzodiazepine derivatives as RSV inhibitors |
WO2020210246A1 (en) | 2019-04-09 | 2020-10-15 | Enanta Pharmaceuticals, Inc, | Heterocyclic compounds as rsv inhibitors |
US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
CA3153297A1 (en) | 2019-10-04 | 2021-04-08 | Adam SZYMANIAK | Antiviral heterocyclic compounds |
US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
UY39032A (en) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS |
WO2022010882A1 (en) | 2020-07-07 | 2022-01-13 | Enanta Pharmaceuticals, Inc, | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors |
US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
AU2022227674A1 (en) | 2021-02-26 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
CN117263873A (en) * | 2022-06-15 | 2023-12-22 | 复旦大学 | 1, 4-benzodiazepine compounds and application thereof in preparation of antitumor drugs |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0349949A2 (en) * | 1988-07-07 | 1990-01-10 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2457405A (en) * | 1945-09-25 | 1948-12-28 | Monsanto Chemicals | Halo nitroparaffin modified aminoplasts |
DE1810423U (en) | 1960-01-05 | 1960-04-28 | Kaiserslautern Guss Armatur | CHIMNEY CLEANING PLUG. |
US3261828A (en) | 1962-10-04 | 1966-07-19 | Hoffmann La Roche | 3h-1,4-benzodiazepine-2,5(1h,4h)-dione compounds |
US3374264A (en) * | 1962-10-04 | 1968-03-19 | Hoffmann La Roche | N-haloacetyl-anthranilic acids and esters |
FR1497456A (en) * | 1964-06-15 | 1967-10-13 | Clin Byla Ets | Ortho-amino aryl ketimines, heterocyclic compounds attached to them and preparation of these various bodies |
NO120269B (en) * | 1965-11-02 | 1970-09-28 | Hoffmann La Roche | |
US3415814A (en) | 1966-09-28 | 1968-12-10 | Sterling Drug Inc | 4-(cyclopropylmethyl)-3h-1,4-benzodiazepine-2,5(1h,4h)-dione |
US3384635A (en) | 1966-09-28 | 1968-05-21 | Sterling Drug Inc | 1, 4-benzodiazepine derivatives |
AT280290B (en) | 1967-11-24 | 1970-04-10 | Boehringer Sohn Ingelheim | Process for the preparation of new 1-phenyl-4-alkyl-3H-1,4-benzodiazepine-2,5- [1H, 4H] -diones |
US4108852A (en) * | 1969-03-18 | 1978-08-22 | Knoll Ag. | Process for preparing 1,5-benzodiazepine-2-ones |
USRE30293E (en) * | 1969-03-18 | 1980-06-03 | Knoll A.G. | Process for preparing 1,5-benzodiazepine-2-ones |
GB1363735A (en) | 1970-10-23 | 1974-08-14 | Hoechst Ag | Process for the manufacture of benzimidazolones |
GB1324469A (en) * | 1970-10-28 | 1973-07-25 | Knoll Ag | Derivatives of benzodiazepines |
US3806594A (en) * | 1972-11-24 | 1974-04-23 | Abbott Lab | Method of reducing involuntary movements associated with cerebral palsy using clorazepate dipotassium |
ZA7465B (en) * | 1973-01-16 | 1974-11-27 | J Voorhees | Proliferating skin diseases with acyl derivatives of cyclic adenosine monophosphate |
IE38931B1 (en) | 1973-03-09 | 1978-07-05 | Lipha | Triazolobenzodiazepines |
US4110327A (en) * | 1974-05-09 | 1978-08-29 | Toyama Chemical Co., Ltd. | 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives |
US4076823A (en) | 1977-08-18 | 1978-02-28 | E. R. Squibb & Sons, Inc. | Triazolo-2,4-benzodiazepines |
JPS59112984A (en) * | 1982-12-21 | 1984-06-29 | Shionogi & Co Ltd | 1,4-benzodiazepine derivative |
US4495101A (en) | 1983-04-28 | 1985-01-22 | American Home Products Corporation | Antiinflammatory 5H-tetrazolo (5,1-c)(1,4)benzodiazepine derivatives |
US4551480A (en) * | 1983-06-21 | 1985-11-05 | Stiefel Laboratories, Inc. | Compositions for the treatment of psoriasis |
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
US5004741A (en) * | 1984-06-26 | 1991-04-02 | Merck & Co., Inc. | Methods of antagonizing CCK or gastrin with benzodiazepine analogs |
DE3435974A1 (en) * | 1984-10-01 | 1986-04-10 | Boehringer Ingelheim KG, 6507 Ingelheim | PHARMACEUTICAL COMPOSITIONS CONTAINING DIAZEPINE WITH PAF-ANTAGONISTIC EFFECT |
FR2591596B1 (en) * | 1985-12-13 | 1988-09-09 | Roussel Uclaf | NOVEL 4H-TRIAZOLO (4,3-A) (1,4) BENZODIAZEPINES, THEIR PREPARATION PROCESS, THEIR APPLICATION AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM |
GB8608080D0 (en) * | 1986-04-02 | 1986-05-08 | Fujisawa Pharmaceutical Co | Solid dispersion composition |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4751223A (en) | 1986-10-14 | 1988-06-14 | Hoechst-Roussel Pharmaceuticals, Inc. | Antiinflammatory and analgesic aminoalkyl tetracyclic benzodiazepines |
US4898861A (en) * | 1987-03-26 | 1990-02-06 | Hoffmann-La Roche Inc. | Method for inhibiting the proliferation of tumor cells |
US5147872A (en) * | 1987-06-09 | 1992-09-15 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically psoriasis |
WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
US5258510A (en) * | 1989-10-20 | 1993-11-02 | Otsuka Pharma Co Ltd | Benzoheterocyclic compounds |
US5041438A (en) | 1989-10-30 | 1991-08-20 | Hoffmann-La Roche Inc. | Method for treating retroviral infections with benzodiazepine compounds |
US5324726A (en) | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
ATE145208T1 (en) * | 1990-07-06 | 1996-11-15 | Yoshitomi Pharmaceutical | CONDENSED THIOPHENE COMPOUNDS AND THEIR USE |
GB9015879D0 (en) * | 1990-07-19 | 1990-09-05 | Fujisawa Pharmaceutical Co | Benzodiazepine derivatives |
BR9200951A (en) * | 1991-03-21 | 1992-11-17 | Hoffmann La Roche | COMPOUNDS, PROCESS FOR ITS PRODUCTION, PHARMACEUTICAL PREPARATIONS AND USE |
CA2130195A1 (en) | 1992-03-16 | 1993-09-30 | Mark Gary Bock | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US5288514A (en) * | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
GB9307527D0 (en) * | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
US5391566A (en) * | 1993-07-20 | 1995-02-21 | Merck & Co., Inc. | Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US5444092A (en) * | 1994-07-20 | 1995-08-22 | Collins; Jerry | Method and composition for treating psoriasis |
US5763437A (en) * | 1994-07-29 | 1998-06-09 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
EP0776203A4 (en) * | 1994-08-18 | 1997-12-29 | Merck & Co Inc | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
US5618792A (en) | 1994-11-21 | 1997-04-08 | Cortech, Inc. | Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase |
WO1996036361A1 (en) | 1995-05-18 | 1996-11-21 | The Regents Of The University Of Michigan | Dna binding antibodies |
US5692337A (en) * | 1995-06-07 | 1997-12-02 | Motz, Jr.; Ronald W. | Collapsible plant shelter |
US5677282A (en) * | 1995-06-07 | 1997-10-14 | Proscript, Inc. | Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase |
US5962337A (en) | 1995-06-29 | 1999-10-05 | Pharmacopeia, Inc. | Combinatorial 1,4-benzodiazepin-2,5-dione library |
RU2096044C1 (en) | 1995-07-19 | 1997-11-20 | Малое предприятие "Ветта" | Veterinary implantable preparation for regulation of biological rhythm in animals |
US5776946A (en) | 1995-08-28 | 1998-07-07 | Mcgeer; Patrick L. | Peripheral benzodiazepine receptor ligands as antiinflammatory agents |
AU721860B2 (en) | 1995-08-30 | 2000-07-13 | La Jolla Institute For Allergy And Immunology | Therapy for cellular accumulation in chronic inflammatory diseases |
US5929069A (en) * | 1995-09-21 | 1999-07-27 | Institute Of Medicinal Molecular Design, Inc. | Compounds activating pharmacological effects of retinoids |
US6579854B1 (en) * | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
UA60311C2 (en) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Vitronectin receptor antagonists |
US7351421B2 (en) * | 1996-11-05 | 2008-04-01 | Hsing-Wen Sung | Drug-eluting stent having collagen drug carrier chemically treated with genipin |
JP3999819B2 (en) * | 1996-12-10 | 2007-10-31 | ゼリア新薬工業株式会社 | 1,5-Benzodiacepine derivatives |
US6074859A (en) * | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
NZ502362A (en) * | 1997-10-08 | 2001-05-25 | Isotechnika Inc | Deuterated cyclosporine A derivatives and their use as immunomodulating agents |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
FR2772271B1 (en) | 1997-12-11 | 2000-09-01 | Union Pharma Scient Appl | NEW PHARMACEUTICAL ASSOCIATION WITH ANALGESIC ACTIVITY |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
WO1999058117A1 (en) * | 1998-05-13 | 1999-11-18 | Sanofi-Synthelabo | Use of compounds for reducing apoptosis |
FR2779963A1 (en) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | New composition useful for treat cancer, comprises compound with affinity for mitochondrial benzodiazepine receptors and agent to induce apoptosis |
US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US20030044776A1 (en) * | 1998-09-25 | 2003-03-06 | James A. Dykens | Compositions and methods for identifying agents that alter mitochondrial permeability transition pores |
FR2785803B1 (en) | 1998-11-17 | 2005-03-25 | Sanofi Sa | USE OF A SUBSTANCE BINDING TO THE PERIPHERAL RECEPTOR OF BENZODIAZEPINES IN THE TREATMENT OF SKIN STRESS |
US7175953B2 (en) * | 1999-04-09 | 2007-02-13 | Institute Fuer Diagnostik Forschung | Short-warp peptide-dye conjugate as contrast agent for optical diagnostic |
US20040176358A1 (en) * | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
DK1143946T3 (en) | 1999-04-30 | 2004-06-07 | Univ Michigan | Use of benzodiazepines for the treatment of autoimmune diseases induced by apoptosis |
US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
US20060025388A1 (en) * | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
US20050113460A1 (en) | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7572788B2 (en) * | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7276348B2 (en) * | 1999-04-30 | 2007-10-02 | Regents Of The University Of Michigan | Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof |
WO2001004103A1 (en) | 1999-07-13 | 2001-01-18 | F. Hoffmann-La Roche Ag | Benzazepinones and quinazolines |
US6524623B1 (en) * | 1999-11-12 | 2003-02-25 | Milton Hodosh | Therapeutic compositions and methods of use thereof |
AU2001255709A1 (en) * | 2000-05-11 | 2001-11-20 | Eastman Chemical Company | Acylated cyclodextrin guest inclusion complexes |
US20020048566A1 (en) * | 2000-09-14 | 2002-04-25 | El-Deiry Wafik S. | Modulation of cellular apoptosis and methods for treating cancer |
CA2432825A1 (en) | 2000-12-15 | 2002-06-20 | Emory University | Nonpeptide agonists and antagonists of vasopressin receptors |
AU2002317910B2 (en) * | 2001-06-07 | 2008-06-19 | Via Pharmaceuticals, Inc. | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof |
NZ531117A (en) | 2001-08-15 | 2006-03-31 | Univ Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
WO2003050261A2 (en) * | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
WO2003106628A2 (en) * | 2002-06-17 | 2003-12-24 | Bristol-Myers Squibb Company | Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase |
US7150433B2 (en) * | 2002-08-16 | 2006-12-19 | Toyota Motor Sales, U.S.A., Inc. | Aircraft bolster trays |
US7109224B2 (en) * | 2002-11-06 | 2006-09-19 | Bristol-Myers Squibb Co. | Acyl guanidine compounds and use thereof |
US20040087489A1 (en) * | 2002-11-06 | 2004-05-06 | Antonio Ruiz | Compositions and methods for the treatment of mycobacterial infections |
AU2003293405A1 (en) * | 2002-12-03 | 2004-06-23 | Vela Pharmaceuticals, Inc. | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof |
ATE440827T1 (en) | 2002-12-04 | 2009-09-15 | Ore Pharmaceuticals Inc | MELANOCORTIN RECEPTOR MODULATORS |
WO2005004988A2 (en) | 2003-05-01 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7351241B2 (en) * | 2003-06-02 | 2008-04-01 | Carl Zeiss Meditec Ag | Method and apparatus for precision working of material |
US20090275099A1 (en) | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
EP1765325A4 (en) | 2004-07-01 | 2009-08-12 | Synta Pharmaceuticals Corp | 2-substituted heteroaryl compounds |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU2006203946B2 (en) * | 2005-01-03 | 2009-07-23 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU2006309291B2 (en) | 2005-06-01 | 2010-05-27 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
EP1951050A4 (en) | 2005-10-26 | 2011-04-27 | Univ Michigan | Therapeutic compositions and methods |
US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
CA2628193C (en) * | 2005-11-01 | 2012-08-14 | The Regents Of The University Of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US7759338B2 (en) | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
WO2007146167A1 (en) | 2006-06-09 | 2007-12-21 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU2008226532B2 (en) | 2007-03-09 | 2011-09-22 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US8324258B2 (en) | 2007-09-14 | 2012-12-04 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
BRPI0820477A2 (en) | 2007-11-06 | 2015-06-16 | Univ Michigan | Benzodiazepinone compounds useful in the treatment of skin disorders |
-
2000
- 2000-04-27 DK DK00928586T patent/DK1143946T3/en active
- 2000-04-27 IL IL14622200A patent/IL146222A0/en active IP Right Grant
- 2000-04-27 WO PCT/US2000/011599 patent/WO2000066106A2/en active IP Right Grant
- 2000-04-27 EP EP03027484A patent/EP1398033B1/en not_active Expired - Lifetime
- 2000-04-27 AT AT03027484T patent/ATE433752T1/en not_active IP Right Cessation
- 2000-04-27 ES ES00928586T patent/ES2214273T3/en not_active Expired - Lifetime
- 2000-04-27 AU AU46802/00A patent/AU782447C/en not_active Ceased
- 2000-04-27 JP JP2000614991A patent/JP5127096B2/en not_active Expired - Lifetime
- 2000-04-27 EP EP09003224A patent/EP2062583B1/en not_active Expired - Lifetime
- 2000-04-27 DE DE60007960T patent/DE60007960T2/en not_active Expired - Lifetime
- 2000-04-27 DE DE60042425T patent/DE60042425D1/en not_active Expired - Lifetime
- 2000-04-27 EP EP10011671A patent/EP2359831A3/en not_active Withdrawn
- 2000-04-27 US US09/700,101 patent/US7125866B1/en not_active Expired - Lifetime
- 2000-04-27 MX MXPA01011052A patent/MXPA01011052A/en active IP Right Grant
- 2000-04-27 EP EP00928586A patent/EP1143946B1/en not_active Expired - Lifetime
- 2000-04-27 CA CA2372150A patent/CA2372150C/en not_active Expired - Lifetime
- 2000-04-27 PT PT00928586T patent/PT1143946E/en unknown
- 2000-04-27 AT AT00928586T patent/ATE258439T1/en active
-
2001
- 2001-01-22 US US09/767,283 patent/US7220739B2/en not_active Expired - Fee Related
- 2001-10-29 IL IL146222A patent/IL146222A/en not_active IP Right Cessation
-
2005
- 2005-10-27 AU AU2005227385A patent/AU2005227385C1/en not_active Ceased
-
2006
- 2006-10-23 US US11/585,492 patent/US20070036854A1/en not_active Abandoned
-
2007
- 2007-05-25 US US11/807,046 patent/US20090012065A1/en not_active Abandoned
-
2013
- 2013-05-17 US US13/896,876 patent/US8809323B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0349949A2 (en) * | 1988-07-07 | 1990-01-10 | Fujisawa Pharmaceutical Co., Ltd. | Benzodiazepine derivatives |
Non-Patent Citations (6)
Title |
---|
BLUM P ET AL: "Stiff-person syndrome: an autoimmune disease.", MOVEMENT DISORDERS, (1991) 6 (1) 12-20. REF: 40, XP000957552 * |
MALGRANGE: "beta-carbolines induce apoptotic celle death...", NEUROREPORT, vol. 7, no. 18, 1996, pages 3041 - 3045, XP000957563 * |
MILLER K A ET AL: "Benzodiazepines prevent neuronal death by apoptosis and necrosis in the gerbil hippocampus following transient cerebral ischemia.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 24, no. 1-2, 1998, 28th Annual Meeting of the Society for Neuroscience, Part 1;Los Angeles, California, USA; November 7-12, 1998, pages 979, XP000957679, ISSN: 0190-5295 * |
SCHLUMPF: "delayed developmental immunotoxicity of...", TOXICOL. IN VITRO, vol. 8, no. 5, 1994, pages 1061 - 1065, XP000957564 * |
TANIMOTO, YUTAKA ET AL: "Benzodiazepine receptor agonists modulate thymocyte apoptosis through reduction of the mitochondrial transmembrane potential", JPN. J. PHARMACOL. (1999), 79(2), 177-183, XP000957572 * |
TAUPIN V ET AL: "ENDOGENOUS ANXIOGENIC PEPTIDE ODN DIAZEPAM-BINDING INHIBITOR AND BENZODIAZEPINES ENHANCE THE PRODUCTION OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR BY HUMAN MONOCYTES", LYMPHOKINE AND CYTOKINE RESEARCH, vol. 10, no. 1-2, 1991, pages 7 - 14, XP000957571, ISSN: 1056-5477 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7994313B2 (en) | 2005-06-01 | 2011-08-09 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000066106A3 (en) | Use of benzodiazepines for treating autoimmune diseases induced by apoptosis | |
CA2258548A1 (en) | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases | |
BR9901491A (en) | 7-hetero-bicycles [2.2.1] - heptanes. | |
CA2316921A1 (en) | Aryl fused azapolycyclic compounds | |
HUP0203142A3 (en) | Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use | |
CA2216796A1 (en) | Quinazoline derivatives | |
ID22746A (en) | NEW COMPOUNDS | |
ATE208777T1 (en) | (A)-ANNELATED PYRROLE DERIVATIVES AND THEIR APPLICATION IN PHARMACY | |
NO306977B1 (en) | Use of thienol [1,5] benzodiazepine for the treatment of gastrointestinal disorders | |
CA2326970A1 (en) | Acetylene derivatives as anti-inflammatory/analgesic agents | |
ES2196331T3 (en) | MACROCICLICAL CHAIN DERIVATIVES OF 13 ELEMENTS OF ERYTHROMYCINS A AND B. | |
CA2441771A1 (en) | Dihydro-benzo[b][1,4]diazepin-2-one derivatives as mglur2 antagonists i | |
ATE223917T1 (en) | (A)-ANNELATED PYRROLE DERIVATIVES AND THEIR APPLICATION IN PHARMACY | |
NO20013645L (en) | Use of Pyridazino [4,5-b] Indole-1-Acetamide Derivatives for the Preparation of Medicines for the Treatment of Disease-Related Dysfunction of the Peripheral Benzodiazepine Receptors | |
WO1996023769A3 (en) | Heterocyclic compounds possessing 5ht2c receptor antagonist activity | |
ATE178332T1 (en) | BENZOTHIADIAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | |
PT628033E (en) | BENZODIAZEPINE DERIVATIVES USED AS ANTAGONISTS OF CCK-RECEPTORS | |
ID29790A (en) | USE OF IMIDAZO (1,5-a) -PIRIDO (3,2-e) -PIRAZINON AS MEDICINE | |
AR013844A1 (en) | COMPOUNDS DERIVED FROM 3-OXO-PIRIDO [1,2-A] BENCIMIDAZOL-4-CARBOXAMIDE REPLACED IN POSITION 5 WITH RENT CONTAINING HETEROATOMO, - AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM. | |
DK1212119T3 (en) | Use of cyamemazine in the treatment of abrupt discontinuation of benzodiazepines | |
WO2002002521A3 (en) | Aroyl aminoacyl pyrrole compounds and their pharmaceutical use | |
DE69405901D1 (en) | 2, 3-Dihydro-4 (1H) -quinazolinone for gastrointestinal therapies | |
ATE207923T1 (en) | 5H, 10H-IMIDAZO (1,2-A) INDENO (1,2-E) PYRAZINE -4-ONE DERIVATIVES THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM | |
Pozzi et al. | Behavioural screening for potential nootropic drugs | |
BR0010748A (en) | Heterocyclic compounds containing imidazo, their compositions and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 09700101 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000928586 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWP | Wipo information: published in national office |
Ref document number: 2000928586 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2372150 Country of ref document: CA Ref country code: JP Ref document number: 2000 614991 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2372150 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/011052 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 46802/00 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/15-15/15, DRAWINGS, REPLACED BY NEW PAGES 1/15-15/15; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000928586 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 46802/00 Country of ref document: AU |